Koca Süleyman Serdar, Kara Murat, Özgen Metin, Dayanan Ramazan, Demir Caner Feyzi, Aksoy Kader, İlhan Nevin, Dönder Emir, Işık Ahmet
Department of Rheumatology, Fırat University School of Medicine, Elazığ, Turkey.
Department of Medical Genetics, Sıtkı Koçman University School of Medicine, Muğla, Turkey.
Eur J Rheumatol. 2017 Jun;4(2):113-117. doi: 10.5152/eurjrheum.2017.160095. Epub 2017 Jun 1.
Chronic inflammatory diseases are associated with altered body composition. Ghrelin has anti-inflammatory effects, and its level is altered in obesity and inflammatory diseases. The aim of the study was to evaluate the prevalence of obesity and ghrelin and obestatin levels in patients with Behçet's disease (BD).
One hundred and forty-three (143) patients with BD and 112 healthy controls (HC) were enrolled. Participants were subdivided according to the body mass index (BMI) as lean (<18.5 kg/m), normal weight (18.5-24.9 kg/m), overweight (25-29.9 kg/m) and obese (≥30 kg/m). In addition to the routine evaluations (fasting blood glucose, lipid profile, and kidney and liver function tests), serum acylated-ghrelin (AG), unacylated-ghrelin (UAG), total ghrelin (TG) and obestatin levels were analyzed. Student's t-test and chi-square test were used for statistical analysis.
The prevalence of obesity was relatively lower in the BD group than in the HC group (12.6% vs. 20.5%, p=0.089). Serum ghrelin levels were similar in the BD and HC groups (p>0.05 for all) although the obestatin level was higher in the BD group compared to the HC group (p<0.001). Serum UAG, TG and obestatin levels were lower in obese BD patients (n=18) than non-obese BD patients (p=0.027, p=0.014 and p=0.001, respectively).
The obestatin level was high and the prevalence of obesity was low in the BD group. Moreover, obese BD patients had low obestatin levels. These results suggest that obestatin may protect BD patients from obesity.
慢性炎症性疾病与身体成分改变有关。胃饥饿素具有抗炎作用，其水平在肥胖症和炎症性疾病中会发生改变。本研究的目的是评估白塞病（BD）患者中肥胖症以及胃饥饿素和肥胖抑制素水平的患病率。
纳入143例BD患者和112例健康对照者（HC）。参与者根据体重指数（BMI）分为消瘦（<18.5kg/m）、正常体重（18.5 - 24.9kg/m）、超重（25 - 29.9kg/m）和肥胖（≥30kg/m）。除了常规评估（空腹血糖、血脂谱以及肾和肝功能检查）外，还分析了血清酰化胃饥饿素（AG）、去酰化胃饥饿素（UAG）、总胃饥饿素（TG）和肥胖抑制素水平。采用学生t检验和卡方检验进行统计分析。
BD组肥胖症的患病率相对低于HC组（12.6%对20.5%，p = 0.089）。BD组和HC组的血清胃饥饿素水平相似（所有p>0.05），尽管BD组的肥胖抑制素水平高于HC组（p<0.001）。肥胖的BD患者（n = 18）的血清UAG、TG和肥胖抑制素水平低于非肥胖的BD患者（分别为p = 0.027、p = 0.014和p = 0.001）。
BD组肥胖抑制素水平较高而肥胖症患病率较低。此外，肥胖的BD患者肥胖抑制素水平较低。这些结果表明肥胖抑制素可能保护BD患者不患肥胖症。
